Joern

Biography

JOERN leads the amazing Hookipa Biotech team as Chief Executive Officer. Before joining Hookipa in June 2016, Joern was CEO of NASDAQ-listed uniQure N.V, a company pioneering adeno-associated virus-based gene therapy. Under his leadership from 2009-2015, uniQure received the first-ever approval of a gene therapy product by the European Medicines Agency, built a pipeline of gene therapy products across several disease areas, obtained approximately $200M through its NASDAQ-listing and follow-on, and closed a multi-billion dollar collaboration in cardiovascular gene therapy. From 1997-2008, Joern was President and CEO of Evotec AG, where he designed many alliances with leading pharma and biotech companies, listed the Company on the Frankfurt Stock Exchange and NASDAQ, and managed the acquisition of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis Inc. In 2013 Joern co-founded GPCR-company G7 Therapeutics, which was successfully sold to Heptares in 2016.Alongside his CEO role at Hookipa, Joern is Chairman of Molecular Partners AG and a Board member of Unum Therapeutics, both of which are developing next-gen immuno-oncology therapies. Joern holds business degrees from the European Business School and Harvard Business School (AMP).

Research Interest

Immunology